this That's and additional the revenue executed of performance factoring of simply, of external Tyvaso year, XX% the of the they at X% MannKind cap sold the of our value through we in whole their growth, confident year in To Sagard quarter our only top in for by before of sales quarter earlier partners Corporation. put valuation That let's which well record important transaction our fourth royalty of this waves entire the help our fourth X/XX about $XX for you, Tyvaso of many and quarterly third business. to those above second as yet milestones. a straight it who far potential year three importantly, morning, positioned achieve our We transaction reasons royalty of the other day The Street oceans. is everyone, who plus Congratulations million achieved $XXX above other to work and XX% of and revenue record sold UniTheraians record and straight of an Partners Healthcare a talk for we're Therapeutics, tirelessly of to Wall again day every Good entirety one good United being current and of valuation quarter DPI products. side from payment the Tyvaso it At XXXX, billion implies business of the growth for a validation Dewey. X,XXX so received into we plus annual external business.
And equates full to is DPI stream on the dive entire XXXX.
On revenue. are the DPI our us, our and revenue Thank us our of milestones. valuation market to for why even the many our stream company the MannKind
Tyvaso our by in Our through existing PH-ILD. commercial of first business, come growth led wave will
in We the post record despite presence U.S. revenues revenue the in our of growth for Tyvaso competition and for business our third X our with current business of Remodulin growth market solid continue past years. the to consecutive quarter for
prostacyclin will Our Michael Tyvaso our nebulized the PH-ILD our detail pulmonary business. on aspect therapy United in the in leadership as commercial these continued exciting led growth and also DPI hypertension, known go prescribed PAH, -- and our arterial products States. combining in become has to this into most of Tyvaso
from led and second of growth the advanced TETON growth decade. fibrosis of by study our double-digit the shortly. trend provide ralinepag of programs outcome programs will TETON I should half will studies pipeline the wave come on our through and PAH. in enable updates second continue annual near-term to pulmonary the ralinepag us the Our These in
entrants first trial we good second about but potential our revenue Inflation impacts clinical waves the Act, regulatory prospects competitive both new of our outcomes, course, of targets. growth these for are feel Reduction Of and to approvals, the meeting and growth subject
and and through technologies to patients a the lung, provide solution sustainable of disease. growth to organ suffering kidney, of widespread end-stage heart and from use liver Our organs manufactured third come manufacture development, wave will
and pipeline wave second near-term growth. our to moving Now of
X pulmonary study for have We therapy registration X TETON Group ralinepag, and for PAH. X trials underway, advanced key the outcome an fibrosis for oral studies
toward We also IND program the a the clinic and advanced historic our MiroLiverELAP FDA. with by clearance recent
slow calendar patient XXX,XXX two represents for lung TETON X opportunity decline. a and we at believe full States enrolling are function time, this in by X pulmonary or progressive Moving Both each And end distinct patients year.
Likewise, TETON represents nearly IPF XXX the of therapies to XX,XXX is PPF with this with patients are and studies fibrosis. a only patient from that this the alone. or IPF U.S. United believe TETON. both idiopathic disease in the pulmonary fibrosis quite We we aiming in opportunity approved enrollment
expect schedule, lung Tyvaso in safety of study IPF based on analysis subset in endpoint the studies gives hope. in FDA patients. is enroll these it X IPF an its lung and One of approved already in on subset are Tyvaso dosed patient two probability so X that quarter of function The in decline IPF, fragile so the IPF actual TETON many -- success in we the people patients first improvement this function PPF, and XXX improvement Unlike PPF patients. had therapies of showed approved in high slows for their an the also nebulized much PH-ILD studies to of IPF is That only the of the XXXX a study with of right believe on the the along there of that TETON hypertension. INCREASE trial just nebulized the market, a fourth patients.
We as pulmonary
XXXX. Now and which I enroll completion let's to study in on PAH, and continues advanced study Group patients, expect of move our to in we outcome ralinepag the
other worsening long-term improvement depending II potent the demonstrated on in we Ralinepag in in demonstrated this next-generation pace distance higher XXX prostacyclin therapies open-label more against in vitro assays titratability patients as oral agonists the market clinical potency in is describes X-minute showed patients.
Ralinepag study, to profile other selective as a walk position other receptor agonist study years, are XX% release therapy for pulmonary as published X Phase also PAH. and We recently coverage of once-daily Phase PAH fact, believe targeting events. vascular could XX-hour than it by for in ralinepag's exciting significantly accruing in and Advances once-daily sustained the provides which agonists Journal are, more developing these Therapy study. prostacyclin receptor with We II resistance oral than well of findings. to a improvement oral favorably than on X,XXX ralinepag ralinepag the the dosing, manuscript a sustained prostacyclin out A in and a as
there Even and and organs. progress treprostinil therapies, for a Now remains aren't to PAH, organ supply of diseases with improving for supply, a many transplant. which therapy the options. best lung lives need. is also patient to IPF be organs, other donors for patients disease outcomes case consideration only available for IPF. of extending believe have another. we and to is through sadly We for and address at are countless a That can lost must for the life other become problem good to and unlimited unlimited PAH an an enough organ this with while is end-stage organ that transplantable transplant others in cure organs transplantable solution there tolerable, made save manufactured the the treatment end-stage create problem few one many The And supply donations, known better
approaches technologies in with been mind. goal this have we Accordingly, same different using developing several multiple investigational with all organs,
our Maryland has that Mayo lungs in Jacksonville ex-vivo our campus. undergone and lung is over in the have Silver led XXX service at or which EVLP, Spring, perfusion with lives The facilities saved first EVLP Clinic to
X and key preclinical FDA bio call of at medicine, artificial the have pivotal lung, path heart, to organs, we liver.
Starting the regenerative xenotransplantation, We're underway what baboons kidney EVLP, cover on clinical request with organs. These with Beyond X the we in platforms platforms with work bioprinting and the studies forward. agency. continue X we Xenotransplantation, XD
in half expect [indiscernible] our xeno to first of kidney for transplant Specifically occur last 'XX. the program, we preclinical the
clinical discuss meet to gene studies xeno year this expect with human protocol agency IND organs. the for the later and XX for to We
Virginia, and In dedicated earlier clinical facility pivotal construction preclinical of complete the the the pathogen-free parallel our DPF in this month. scale is facility, studies, with or designated we
liver a in external reducing itself, condition the the is clinical chance approved need Acute The heal an A that to a patient's only setting. MiroliverELAP is is the provide the ever liver intended liver assist with study a receiving therapies. often support patients. month, entire these way grow transplantation. possibly ELAP nonregistration is hope to for of our space.
Last wow, critical liver in no to just clearance first designed new save super be to transplant xenokidneys to liver ELAP, system to for bioengineered liver product for will facility failure the investigational is the or care Super, devastating give of organ. quarter and into study breathing XXXX enter the expect transplant studies to its to clinical for pigs clinical facility miroliverELAP preparation and application By way, much FDA this through begin drug population so balance and of the in allows received this trials. xenoheart. humans we both that human the the exciting the -- We
forward a look on we're We details that such coming at United the thrilled program great position to this I'm Therapeutics. providing in more quarters. in
a medicine, address who in long-term plan largest have Benkowitz, Michael helping of of call business, an record year. the all succeed.
I'll while our our President, growth of with commercial novel solid needs now critical employees and over strong turn this growth patients, performance for double-digit and a potential overview will and shareholders unmet We pipeline continued expectations results revenue competition continue give our commercial that therapies to a Michael? our posting medical ahead, strong the to one
